We studied the prevalence and the effect of coagulation factor V Leiden mutation on the occurrence of thrombotic episodes in 120 Hungarian patients having systemic lupus erythematosus (SLE) with or without antiphospholipid antibody.
Summary: We studied the prevalence and the effect of coagulation factor V Leiden mutation on the occurrence of thrombotic episodes in 120 Hungarian patients having systemic lupus erythematosus (SLE) with or without antiphospholipid antibody.
The frequency of the factor V Leiden mutation in Hungarian SLE patients was 13%, which is comparable with those found previously in a healthy Caucasian population. The incidence of venous thrombosis among factor V Leiden carriers has been found to be higher (odds ratio [OR] 1.7) than it is in patients without Leiden mutation (38% vs 29%). In addition, the frequency of venous thrombosis in the heterozygous SLE patients (OR 8.4 [confidence interval (CI) 0.8-83.9] P=0.06) is dependent on the coexistence of other risk factors, such as antiphospholipid antibody. Moreover, among heterozygous factor V SLE patients, the Leiden mutation could explain the tendency to have significantly higher prevalence of fetal losses (OR 3.9 [CI 1.2-12.0] P = 0.02) and higher prevalence of cerebrovascular lesions, cardiac valvular abnormalities, and Raynaud's syndrome than that found in individuals without factor V Leiden mutation or those having antiphospholipid antibody.
Systemic lupus erythematosus patients with combined defects suffer more severely from thrombosis than those with a single risk factor do, suggesting that thrombophilia is a multifactorial disorder in SLE, also. Although, the factor V Leiden mutation does not seem to be a significant risk factor for venous thrombosis in SLE, these data demonstrate that Leiden mutation can be regarded as an additive thrombogenic factor providing higher predisposition to several vasoocclusive disorders in SLE. Key words: Activated Protein C Resistance&mdash; Antiphospholipid Antibody&mdash;Systemic Lupus Erythemato-sus&mdash;Thrombosis.
Systemic lupus erythematosus (SLE) is strongly associated with a history of various coagulation disorders, particularly those presenting secondary antiphospholipid syndrome (1) (2) (3) . The activated protein C (APC) resistance is the most common inherited risk factor for venous thrombosis and most cases of genotypic APC resistance are caused by the factor V Leiden (FVL) mutation (4) (5) (6) . The prevalence of FVL in the Hungarian healthy population is one of the highest in Europe (7) (8) (9) .
Nevertheless, the role of FVL in various vasoocclusive
disorders is still controversial (10) (11) (12) (13) (14) (15) (16) . The clinical relevance of APC resistance in autoimmune disorders is related to two different aspects. Acquired APC resistance phenotype is common in antiphospholipid syndrome (17) (18) (19) (20) 25) . There are possibly some mechanisms the protein C pathway involved, contributing to a hypercoagulable state (17) (18) (19) (20) 22, 23) . In addition to other condi-tions, such as the presence of antiphospholipid antibodies (aPL), gender, pregnancy, and so on, may lead to APC resistance phenotype without altered genotype (17, 18, 22, 23) . In these cases, the molecular diagnosis is relevant to detect FVL mutation, but combined thrombophilic risk factors could be present (21, (23) (24) (25) . The acquired coagulation defect resulting in APC resistance phenotype could play a major role in the pathogenesis of thrombosis in antiphospholipid syndrome that is closely related with SLE (17) (18) (19) (20) (21) (22) 24, (26) (27) (28) (29) .
Investigating the background of thrombophilic episodes in Hungarian SLE patients, the screen for the Leiden mutation as a lifelong carried risk factor should be an important tool, also. According to our hypothesis, SLE patients carrying both the FV Leiden mutation and aPL may have a multiple predisposition to thrombotic episodes (28, 29) .
The aim of this present work is to report the frequency of Leiden mutation in Hungarian SLE patients and the significance of FVL mutation in the development of venous and arterial thrombotic diseases in SLE with or without secondary antiphospholipid syndrome.
MATERIALS AND METHODS

Patients
One hundred and twenty patients (107 females, 13 males; mean age: 35.93±13.15; age at diagnosis: 25 to 60 years) with SLE were studied. They all fulfilled the modified American Rheumatism Association (ARA) criteria for SLE (30) . The diagnosis was established between 1961 and 1997. The mean follow-up time was 11±11 years (6 months to 37 years). Blood samples were measured in at least two separate serologic tests spaced at more than 3 months intervals between 1993 and 1997.
Clinical data were obtained retrospectively from medical records of all SLE patients. In the cases of a positive Doppler ultrasound or a positive phlebography, the diagnosis of deep vein thrombosis (DVT) was established.
Vasoocclusive disorders in the arterial side were detected with Doppler ultrasound. Pulmonary embolism (PE) was diagnosed with pulmonary scintigraphy plus chest radiograph. Sinus thrombosis and vascular lesions in central nervous system (CNS) were diagnosed with CT and MRI. Heart diseases, called valvulopathies in this study, were examined by transthoracal and transoesophageal echocardiography (two-dimensional and Doppler ultrasound).
Detection of factor V mutation by polymerase chain reaction DNA was extracted from whole venous blood. Polymerase chain reaction (PCR) was done to amplify the region flanking the G to A substitution at position 1691 1 in the factor V gene. The PCR products were digested by Mnll restriction endonuclease. The restriction products were separated on a 3% agarose gel electrophoresis as described by Bertina et al. (5) .
Activated protein C ratio assay
This test was done according to Dahlbdck by using the APC resistance test of Stago (Asnieres, France) (4). First, activated partial thromboplastin time (APTT) was measured, and then APC was added, and the APTT was measured again. The ratio of the APTT in the presence of APC to the APTT without added APC was determined.
Phenotypic APC resistance was defined as a ratio below 2.0.
Detection of antiphospholipid antibodies
Anticardiolipin antibodies (aCL) were tested with enzyme linked immunosorbent assay (ELISA), by the standard method. Briefly, wells were coated with 5 [Lg of CL (Sigma; St. Louis, MO) dissolved in absolute ethanol. Sera were applied in 1:40 dilution in duplicates. Nonspecific binding for each serum was determined in CLfree wells, and values were subtracted from specific absorbencies. For diluting the samples and blocking the plates, we applied 10% adult bovine serum (ABS) in phosphate buffered saline (PBS). We constructed an im-munoglobulin (Ig) calibration curve, using human purified IgG/M. Results were expressed as p,g/ml IgG equivalent. The cut-off value on the basis of evaluating healthy control sera was 47 >g/ml for IgG and 70 p,g/ml for IgM aCL, respectively. These values are consistent with the mean plus 3 standard deviations (SD) of the normal controls. Anticardiolipin antibodies positivity was measured in cases of IgG-and/or IgM-positive values (31) . Lupus anticoagulant (LA) was screened by conventional APTT (Stago; Asnieres, France) when it could not be corrected by adding normal plasma to the reaction. This was followed by the diluted thromboplastin time ratio test, diluted Russell's viper venom test, and/or platelet neutralization procedure (American Diagnostica; Greenwich, CT, USA) to verify the presence of LA.
All the analyses were performed with Statistical Analysis Software (SAS PHREG) for Windows (6.12). The significance of differences was evaluated by the Fisher's exact probability test (zs. Karanyi; Debrecen, Hungary). A two-sided P value that was less than 0.05 was considered to be statistically significant. Odds ratios and 95% CIs by SAS PHREG were calculated. ' 
RESULTS
The heterozygous form of the FVL mutation was detected in 16 patients (13.3%, 14 female, 2 male, mean age: 39±14 years at the diagnosis, mean follow-up time: 6.9±8.2 years). We did not find any homozygous form. The mean functional APC ratio was 1.6±0.12, thereby showing phenotypic APC resistance. Six patients heterozygous for FVL (37.5%) presented at least one DVT during their disease courses. Three (18.75%) FVL heterozygous patients with DVT had some kind of aPL, either LA and/or aCL. Two heterozygous patients with LA had multiple DVT; one of them had the third venous thrombosis in the right upper extremity. Altogether 2 reported patients had venous thrombosis in unusual locations, such as in the upper extremities. Moreover, in 25% of aPL-negative FVL carriers, (n = 12) presented at least one DVT. None of FVL carriers had PE (Table 1 ). Five patients (n = 2 heterozygous) were taking oral anticoagulation medication at the time of sampling, resulting in phenotypic APC resistance (APC ratio<2.0). The remaining SLE patients studied (n = 104, 86.6%, 93 female, 11 male) proved to be carrying a normal coagulation factor V (mean age: 36±13 years at the diagnosis, mean follow-up time: 12±11 years). The mean APC ratio was 2,28 ± 0.32, showing no signs of phenotypic APC resistance. Thirty patients (28; 34%) experienced DVT at least once during the follow up time. In seven cases (6; 7%) multiple DVT was documented and 6 patients (5; 7%) had suffered from PE (Table II) .
Fifty-six out of 104 SLE patients proved to be aPL positive and in 18 (32.1%) cases DVT was determined. was positive for aPL. In the background of hypercoagulability hereditary APC resistance-without any other predisposing factor-was registered in 3 (8.3%) thrombotic cases. The presence of the factor V Leiden mutation did not increase significantly the occurrence of venous thromboembolic manifestations in SLE (OR 1.68, CI 0.56-5.02, P = 0.37). Three SLE patients with venous thrombotic events (8.3%) had both congenital and acquired form of APC resistance (OR 8.4, CI 0.84-83.9, P = 0.06). The rest of the thrombotic group (n = 12; 33.3%) had neither aPL antibody nor FVL mutation. The DVT developed between 9.8 ± 12.9 years interval following the onset of SLE. There were few cases with unusual sites of thrombotic events, such as thromboses in the upper limb (n = 2), dural sinus thrombosis (n = 1) and central retinal vein thrombosis (n = 1). Both patients with upper limb thrombosis proved to be heterozygous for FV Leiden mutation.
In present work, we studied several different clinical manifestations of antiphospholipid syndrome in SLE, including arterial thrombotic episodes: acute myocardial infarction (AMI), ischaemic stroke or multiple vascular lesions (CNS disorders), spontaneous abortions and others : cardiac valvular abnormalities, livedo reticularis, thrombocytopenia and Raynaud's phenomenon (Table 11 ). The incidence of vascular manifestations in CNS (31.3% vs 26.9%) with an OR 1.23 (CI 0.39-3.86), heart valve disorders (25% vs 19.2%) with an OR 1.44 (CI 0.4-4.8) and Raynaud's phenomenon (37.5% vs 31.7%) with an OR 1.29 (CI 0.43-3.85) were higher in patients group with FVL than these data in the SLE group with normal FV genotype. Nevertheless, there were no statistically significant differences in the analysed data between these groups (Table II) .
The proportion of SLE females with spontaneous abortions (25.0% vs 11.8%) with an OR 2.98 (CI 0.79-11.15) and the frequency of fetal losses out of the number of pregnancies in females with FVL was higher (10/ 16, 63% vs 21/70, 30%) with an OR 3.88 (CI 1.25-12.08, P = 0.02) compared to number of miscarriages in the group of females having normal FV genotype. The frequency of fetal losses among FVL carrier SLE females was statistically significant.
The other clinical data were not showed because of the relatively low numbers of cases in each groups. We detected 16 patients with thrombocytopenia (1 vs 15), 3 individuals with peripheral arterial occlusion (1 vs 2) and only 4 SLE patients with AMI (1 vs 3).
However, SLE patients with aPL positivity had suffered from livedo reticularis more frequently than the other presented SLE patients.
DISCUSSION
The inherited resistance to activated protein C was first described by Dahlbdck in 1993 (4) . It was identified as a single base mutation in the gene coding coagulation factor V at a predominant cleavage site 1691 for APC (5) . The presence of the heterozygous form of Leiden mutation increases the relative risk of DVT 8 to 10 fold however, the homozygous form causes an 80 to 100 fold elevation (32) . Unlike some studies reported the absence of an association between the presence of FV Leiden mutation and cardiovascular diseases (14, 15) , other recent data suggest the hereditary APC resistance can be associated with different vascular disorders as recurrent fetal losses, cerebrovascular events and myocardial infarction (10) (11) (12) (13) 16, 25, 28, 29) . Holm et al. demonstrated a gene-environment interaction with an increased risk of coronary thrombotic complications (13) , proposed the second-hit hypothesis between hereditary thrombophilias and/or acquired risk factors (21, 24, 25, 28, 29) . This pathogenic interaction could be common in autoimmune patients with antiphospholipid antibody. The different clinical presentations of coagulation disorders are depending on the risk factor profile: genetic defects and acquired triggering conditions (21, 23, 24, 25, 28, 29) . Several authors have reported the inhibitory effect of aPL on both the activation of protein C and the degradation of factor V by APC (18) (19) (20) 22) . This mechanism seems to be one of the possible causes of thrombosis in SLE with aPL antibody (19, 22) . Thus, we studied the prevalence of factor V Leiden and the additional role of Leiden mutation on the development of haemostatic imbalance in SLE patients (26) (27) (28) . The epidemiological studies have determined the prevalence of FV mutated gene in the various populations and it is hypothesized that the Leiden mutation has originated and accumulated in European Caucasians (3%--9%) (8, 9, 10, 33, 34) . The frequency of Leiden mutation is 9% to 10% in the Hungarian asymptomatic population (7) (8) (9) . We presented the prevalence of FVL mutation 13.3% among Hungarian SLE patients in fact that is similar to those described previously.
The heterozygous FV Leiden carriers had slightly increased frequency of DVT compared to the group of patients having normal FV genotype. The Leiden mutation may raise the possibility of the thrombosis at unusual sites as the upper extremities in SLE.
In the present study SLE patients with aPL had previous history of DVT and/or PE. The FVL carriers had an increased risk, but FVL carriership combined with aPL positivity pointed to the highest risk (OR 1.68 vs 8.4) for venous thrombosis in examined SLE patients. The presence of LA seemed more strongly correlated with vasoocclusive disorders than aCL positivity.
Whether the carriership of FV Leiden mutation is related to an increased risk of arterial thrombosis is still matter of debate (10) (11) (12) (13) (14) (15) (16) 25, 26) . However, we identified the FV Leiden mutation in the background of arterial side of haemostatic events in SLE, as miscarriages, peripheral arterial occlusion, myocardial infarction and other main clinical signs of APS, vascular lesions in CNS, and cardiac valvular disorders. In addition, the frequency of fetal losses among FVL mutation female carriers was significantly higher than the frequency in SLE females with normal FV.
In conclusion, we documented the relationship between factor V Leiden mutation and various clinical problems of hypercoagulability in Hungarian SLE patients. In this study, the simultaneous existence of heterozygous FV Leiden mutation in SLE seemed to increase the incidence or severity of thrombotic episodes.
Our data suggest, the heterozygous form of FV Leiden mutation in SLE patients with an ongoing prothrombotic tendency may lead to have more manifestations of vascular disorders, similarly that aPL antibody responsible for the clinical symptoms of the antiphospholipid syndrome. The haemostatic imbalance, the frequent and unusual thrombotic episodes can lead to development of serious complications in SLE patients.
From the therapeutic point of view, the FV Leiden mutation carriers having a lifelong risk factor for thromboembolism and the genetic defect combined with acquired in SLE more prolonged anticoagulation should come into consideration (16, (24) (25) (26) 29) .
